The pharmacokinetic behaviour of haloperidol (0.6 mg/kg s.c.) was studied in grouped and 4-week isolated male mice of the CF-1 strain (24 h observation; gaschromatography, NPFID). Maximal drug levels occurred in serum within 2 min and in whole brain after 15 min. The elimination from serum and brain was biphasic with larger t½ values for brain. There was an accumulation of haloperidol in brain up to 40 times of the serum level. Isolation resulted in a more rapid first phase of elimination from serum, provided the animals were tested for aggressivity immediately before the administration of the drug. The minimal effective (i.e. cataleptogenic) brain level of haloperidol was approximately 0.1 µg/g wet weight. Haloperidol-induced catalepsy was (after 1 h) in isolated mice weaker than in grouped mice; this applied to animals of both the CF-1 and the NMRI strain. The catalepsy disappeared after 6 h. The antagonism by haloperidol of the stereotyped gnawing (induced by methylphenidate, 30 and 50 mg/kg, i.p., NMRI mice) likewise lasted for 6 h. Therefore, the cataleptic effects, but not the brain levels of haloperidol, are influenced by isolation and aggression in mice.

Keywords:
Pharmacokinetics, Haloperidol, Mouse, Housing conditions, Isolation, Aggressivity, Catalepsy, Antistereotypic effect
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.